Compare
Prime Medicine, Inc. vs Zeo ScientifiX, Inc. vs CG Oncology, Inc. vs DBV Technologies S.A.
| Latest fiscal year | Prime Medicine, Inc. PRME | Zeo ScientifiX, Inc. ZEOX | CG Oncology, Inc. CGON | DBV Technologies S.A. DBVT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-10-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $4.63M | $5.20M | $4.04M | $5.64M |
| Revenue growth (YoY) | +55.3% | +12.5% | +254.7% | +35.8% |
| Gross margin | n/a | 82.1% | n/a | n/a |
| Operating margin | n/m | -103.6% | n/m | n/m |
| Net margin | n/m | -106.2% | n/m | n/m |
| Net income | -$201.14M | -$5.52M | -$161.00M | -$146.95M |
| EPS (Diluted) | -$1.35 | -$0.86 | -$2.08 | -$1.05 |
| Operating cash flow | -$162.56M | -$718.0K | -$132.35M | -$121.18M |
| Free cash flow | -$167.09M | -$741.0K | -$132.48M | -$121.71M |
| Cash & equivalents | $63.03M | n/a | $32.49M | $194.17M |
| Total assets | $342.73M | $1.53M | $791.59M | $233.72M |
| Total liabilities | $221.87M | $2.95M | $38.99M | $64.95M |
| Shareholders' equity | $120.87M | -$1.42M | $752.60M | $168.77M |
| Return on year-end equity | -166.4% | n/a | -21.4% | -87.1% |
| Shares outstanding | 180.51M | 6.75M | 80.69M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Prime Medicine, Inc. | Zeo ScientifiX, Inc. | CG Oncology, Inc. | DBV Technologies S.A. |
|---|---|---|---|---|
| Latest | $4.63M Ended 2025-12-31 | $5.20M Ended 2025-10-31 | $4.04M Ended 2025-12-31 | $5.64M Ended 2025-12-31 |
| 1 year earlier | $2.98M Ended 2024-12-31 | $4.62M Ended 2024-10-31 | $1.14M Ended 2024-12-31 | $4.15M Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | $4.56M Ended 2023-10-31 | $204.0K Ended 2023-12-31 | $15.73M Ended 2023-12-31 |
| 3 years earlier | $0 Ended 2022-12-31 | $6.49M Ended 2022-10-31 | n/a | $4.84M Ended 2022-12-31 |
| 4 years earlier | $0 Ended 2021-12-31 | $5.60M Ended 2021-10-31 | n/a | $5.71M Ended 2021-12-31 |